Neoadjuvant personalized cancer vaccines: the final frontier?
ABSTRACTIntroduction Clinical trials of personalized cancer vaccines have shown that on-demand therapies that are manufactured for each patient, result in activated T cell responses against individual tumor neoantigens. However, their use has been traditionally restricted to adjuvant settings and la...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2303015 |
| _version_ | 1797358015583617024 |
|---|---|
| author | Guilhem Richard Nicole Ruggiero Gary D. Steinberg William D. Martin Anne S. De Groot |
| author_facet | Guilhem Richard Nicole Ruggiero Gary D. Steinberg William D. Martin Anne S. De Groot |
| author_sort | Guilhem Richard |
| collection | DOAJ |
| description | ABSTRACTIntroduction Clinical trials of personalized cancer vaccines have shown that on-demand therapies that are manufactured for each patient, result in activated T cell responses against individual tumor neoantigens. However, their use has been traditionally restricted to adjuvant settings and late-stage cancer therapy. There is growing support for the implementation of PCV earlier in the cancer therapy timeline, for reasons that will be discussed in this review.Areas covered The efficacy of cancer vaccines may be to some extent dependent on treatment(s) given prior to vaccine administration. Tumors can undergo radical immunoediting following treatment with immunotherapies, such as checkpoint inhibitors, which may affect the presence of the very mutations targeted by cancer vaccines. This review will cover the topics of neoantigen cancer vaccines, tumor immunoediting, and therapy timing.Expert opinion Therapy timing remains a critical topic to address in optimizing the efficacy of personalized cancer vaccines. Most personalized cancer vaccines are being evaluated in late-stage cancer patients and after treatment with checkpoint inhibitors, but they may offer a greater benefit to the patient if administered in earlier clinical settings, such as the neoadjuvant setting, where patients are not facing T cell exhaustion and/or a further compromised immune system. |
| first_indexed | 2024-03-08T14:53:41Z |
| format | Article |
| id | doaj.art-c49a5329643540508e3c44e5426a9e1f |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-08T14:53:41Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-c49a5329643540508e3c44e5426a9e1f2024-01-10T19:09:08ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123120521210.1080/14760584.2024.2303015Neoadjuvant personalized cancer vaccines: the final frontier?Guilhem Richard0Nicole Ruggiero1Gary D. Steinberg2William D. Martin3Anne S. De Groot4EpiVax Therapeutics, Inc., Providence, RI, USAEpiVax Therapeutics, Inc., Providence, RI, USAEpiVax Therapeutics, Inc., Providence, RI, USAEpiVax, Inc., Providence, RI, USAEpiVax, Inc., Providence, RI, USAABSTRACTIntroduction Clinical trials of personalized cancer vaccines have shown that on-demand therapies that are manufactured for each patient, result in activated T cell responses against individual tumor neoantigens. However, their use has been traditionally restricted to adjuvant settings and late-stage cancer therapy. There is growing support for the implementation of PCV earlier in the cancer therapy timeline, for reasons that will be discussed in this review.Areas covered The efficacy of cancer vaccines may be to some extent dependent on treatment(s) given prior to vaccine administration. Tumors can undergo radical immunoediting following treatment with immunotherapies, such as checkpoint inhibitors, which may affect the presence of the very mutations targeted by cancer vaccines. This review will cover the topics of neoantigen cancer vaccines, tumor immunoediting, and therapy timing.Expert opinion Therapy timing remains a critical topic to address in optimizing the efficacy of personalized cancer vaccines. Most personalized cancer vaccines are being evaluated in late-stage cancer patients and after treatment with checkpoint inhibitors, but they may offer a greater benefit to the patient if administered in earlier clinical settings, such as the neoadjuvant setting, where patients are not facing T cell exhaustion and/or a further compromised immune system.https://www.tandfonline.com/doi/10.1080/14760584.2024.2303015Checkpoint inhibitorimmunoinformaticsimmunotherapypersonalized cancer vaccineneoadjuvant therapyneoantigen |
| spellingShingle | Guilhem Richard Nicole Ruggiero Gary D. Steinberg William D. Martin Anne S. De Groot Neoadjuvant personalized cancer vaccines: the final frontier? Expert Review of Vaccines Checkpoint inhibitor immunoinformatics immunotherapy personalized cancer vaccine neoadjuvant therapy neoantigen |
| title | Neoadjuvant personalized cancer vaccines: the final frontier? |
| title_full | Neoadjuvant personalized cancer vaccines: the final frontier? |
| title_fullStr | Neoadjuvant personalized cancer vaccines: the final frontier? |
| title_full_unstemmed | Neoadjuvant personalized cancer vaccines: the final frontier? |
| title_short | Neoadjuvant personalized cancer vaccines: the final frontier? |
| title_sort | neoadjuvant personalized cancer vaccines the final frontier |
| topic | Checkpoint inhibitor immunoinformatics immunotherapy personalized cancer vaccine neoadjuvant therapy neoantigen |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2303015 |
| work_keys_str_mv | AT guilhemrichard neoadjuvantpersonalizedcancervaccinesthefinalfrontier AT nicoleruggiero neoadjuvantpersonalizedcancervaccinesthefinalfrontier AT garydsteinberg neoadjuvantpersonalizedcancervaccinesthefinalfrontier AT williamdmartin neoadjuvantpersonalizedcancervaccinesthefinalfrontier AT annesdegroot neoadjuvantpersonalizedcancervaccinesthefinalfrontier |